GLP-1 Peptide Atlas, by Delfa

CompletedPhase 2

Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

Effect of NNC 90-1170 on 24-hour Glucose and Hormonal Profiles, Gastric Emptying, and Fasting Gluconeogenesis in Type 2 Diabetic Subjects. A Double-blind, Placebo-controlled, Randomised, Cross-over Trial

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Postprandial glucose

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01508923

Org study IDNN2211-1332

Timeline

Milestones

Study first posted2012-01-12estimated

Last update posted2017-01-24estimated

Study start2001-05 (month precision)

Primary completion2002-02actual (month precision)

Study completion2002-02actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetes mellitus

•Diet treated and/or subjects in monotherapy with max. 50 % of maximal dose of sulphonylurea (SU). In addition, subjects in treatment with metformin and/or repaglinide could be included

•Body Mass Index (BMI) maximum 35 kg/m^2

•Fasting plasma glucose 7-15 mmol/l, both inclusive

Exclusion criteria

•Impaired liver function

•Impaired renal function

•Anaemia

•Cardiac disease

•Uncontrolled treated/untreated hypertension

•Recurrent major hypoglycaemia as judged by the Investigator

•Known or suspected allergy to trial product or related products

•Females of child bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures

•Current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness

•Loss of more than 400 ml blood during the three months prior to study start

•Allergy to paracetamol

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Other (unclassified)

Cardiometabolic biomarkers

Safety / tolerability / PK

Glycemic / diabetes

5 endpoints

Primary/protocol endpoint

24-hour glucose profiles after three fixed meals

Postprandial glucose

descriptive, improvement

Secondary/protocol endpoint

24-hour insulin profiles after three fixed meals

descriptive

Secondary/protocol endpoint/low confidence

First phase insulin and maximal insulin secretory capacity

descriptive

Secondary/protocol endpoint/low confidence

EGR (endogenous glucose release) expressed in mg/kg/min

descriptive

Secondary/protocol endpoint/low confidence

GNG (gluconeogenesis) expressed in mg/kg/min

descriptive

Cardiometabolic biomarkers

1 endpoint

Secondary/protocol endpoint

24-hour FFA (free fatty acids) profiles after three fixed meals

Free fatty acids, change

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Adverse events

Treatment-emergent AEs (any)

descriptive, event

Other (unclassified)

3 endpoints

Secondary/protocol endpoint/low confidence

24-hour glucagon profiles after three fixed meals

descriptive

Secondary/protocol endpoint/low confidence

4-hour paracetamol profiles after two fixed meals

descriptive

Secondary/protocol endpoint/low confidence

30-hour NNC 90-1170 profile

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Diabetes2004 May (month)PMID15111485doi:10.2337/diabetes.53.5.1187via CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.